Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michigan Medicaid Gives Preferred Status To SSRIs, Atypical Antipsychotics

Executive Summary

Michigan Medicaid's Rx prior authorization/ supplemental rebate program awards preferred status for drugs in the selective serotonin reuptake inhibitor and atypical antipsychotic classes

You may also be interested in...



Medicare Rx Benefit Would Replace Maryland Senior Drug Program

Maryland plans to end its Senior Prescription Drug Program when the Medicare drug benefit takes effect in 2006

Medicare Rx Benefit Would Replace Maryland Senior Drug Program

Maryland plans to end its Senior Prescription Drug Program when the Medicare drug benefit takes effect in 2006

New York Medicaid Preferred Drug List Would Save $730 Mil., Report Says

A New York State Senate Medicaid Reform Task Force expects that a preferred drug list/supplemental rebate program would save $730 mil. over five years

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel